Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2024
  • Volume: 17
  • Issue: 9

Evaluation of adrenergic neuron inhibition in patients with uncontrolled hypertension

  • Author:
  • Seba Mawafak1, Shn Bashar Zainulabdeen2, Kais A Najem3, Amal Mayyas4, Amjad I Oraibi5, Zahraa Salam Al-Tameemi6, Hany A. Al-Hussaniy6,*, Fatima Akeel Naji6, Ali Hikmat Alburghaif7, Mohammed K. Al Iraqi6, Meena Akeel Naji6
  • Total Page Count: 8
  • Page Number: 4613 to 4620

1Department Family Medicine, College of Medicine, Baghdad, Iraq

2Pharmacy Department Al-Karkh Baghdad Health Department, Ministry of Health, Iraq

3Department of clinical Pharmacy, College of Pharmacy, Univeristy of Baghdad, Iraq

4Department of Pharmacy, Faculty of Health Sciences, American University of Madaba, Madaba, 11821, Jordan

5Al-Manara College for Medical Sciences, Department of Pharmacy, Amarah, Iraq

6Dr Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, 10001, Iraq

7Department of Pharmaceutical Chemistry, Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq

*Corresponding Author E-mail: hanyakeel2018@gmail.com

Online published on 30 April, 2025.

Abstract

Uncontrolled hypertension increases the risk of cardiovascular illnesses and death, among other serious health problems. There are antihypertensive medications available, yet some individuals still don't respond to them. Because of the critical function that adrenaline neurons play in blood pressure control, inhibiting these neurons may offer a treatment option for resistant hypertension.

This study conducted to Evaluation of the Efficacy of nanotecology based therapy as Adrenergic Neurons Inhibition in Patients with Uncontrolled Hypertension.

We was conducted a review article in the role of adrenergic blocker by medication or by surgery, knowing that we was used keywords "Antihypertensive Agents" and "nanotechnology based therapy,", "Adrenergic Neurons", "Ganglia", "Spinal" and "Hypertensive Crisis". in relevant search Engine such as google scholar , ResearchGate, PubMed and so one, we exclude any not relevant article and hypertention in pregnancy and so one.

The nanotechnology-enhanced treatment group showed a significant reduction in systolic and diastolic blood pressure compared to the control group. On average, the treatment group experienced a 20% greater reduction in blood pressure levels. Additionally, patients reported fewer side effects and better overall tolerance to the treatment.

Nanotechnology-enhanced adrenergic neuron inhibition demonstrates substantial promise in managing uncontrolled hypertension. The improved efficacy and reduced side effects suggest that this innovative approach could offer a viable alternative for patients who do not respond well to conventional therapies. Further research and larger clinical trials are warranted to confirm these findings and optimize the treatment protocol.

Keywords

Antihypertensive Agents, Blood Pressure, Adrenergic Neurons, Ganglia, Spinal, Hypertensive Crisis, Hypertension